+

PE20090046A1 - Anticuerpo recombinante humanizado anti-interleuquina 10 - Google Patents

Anticuerpo recombinante humanizado anti-interleuquina 10

Info

Publication number
PE20090046A1
PE20090046A1 PE2008001584A PE2008001584A PE20090046A1 PE 20090046 A1 PE20090046 A1 PE 20090046A1 PE 2008001584 A PE2008001584 A PE 2008001584A PE 2008001584 A PE2008001584 A PE 2008001584A PE 20090046 A1 PE20090046 A1 PE 20090046A1
Authority
PE
Peru
Prior art keywords
antibody
fab
humanized antibody
interleuquin
recombinant anti
Prior art date
Application number
PE2008001584A
Other languages
English (en)
Inventor
Leonard G Presta
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20090046A1 publication Critical patent/PE20090046A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

SE REFIERE A UN ANTICUERPO RECOMBINANTE HUMANIZADO QUE SE UNE A IL-10 QUE COMPRENDE: A) DOS CADENAS LIVIANAS DE ANTICUERPO QUE COMPRENDE UN POLIPEPTIDO QUE TIENE UNA SECUENCIA DE AMINOACIDOS SEQ ID Nº: 14; B) DOS CADENAS PESADAS DE ANTICUERPO QUE COMPRENDE UN POLIPEPTIDO QUE TIENE UNA SECUENCIA DE AMINOACIDOS SEQ ID Nº: 18; C) UNA REGION CONSTANTE DE CADENA PESADA HUMANA ?1, ?2, ?3 O ?4; D) UNA REGION CONSTANTE DE CADENA LIVIANA HUMANA LAMBDA O KAPPA. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE CONTIENE DICHO ANTICUERPO O UN FRAGMENTO DEL MISMO SELECCIONADO DE Fab, Fab', Fab'-SH, Fv, scFv O F(ab')2
PE2008001584A 2003-11-10 2004-11-08 Anticuerpo recombinante humanizado anti-interleuquina 10 PE20090046A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51899903P 2003-11-10 2003-11-10

Publications (1)

Publication Number Publication Date
PE20090046A1 true PE20090046A1 (es) 2009-01-26

Family

ID=34590335

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2008001585A PE20090047A1 (es) 2003-11-10 2004-11-08 Anticuerpo recombinante humanizado anti-interleuquina 10
PE2004001085A PE20050925A1 (es) 2003-11-10 2004-11-08 Anticuerpo recombinante humanizado anti-interleuquina 10
PE2008001584A PE20090046A1 (es) 2003-11-10 2004-11-08 Anticuerpo recombinante humanizado anti-interleuquina 10

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2008001585A PE20090047A1 (es) 2003-11-10 2004-11-08 Anticuerpo recombinante humanizado anti-interleuquina 10
PE2004001085A PE20050925A1 (es) 2003-11-10 2004-11-08 Anticuerpo recombinante humanizado anti-interleuquina 10

Country Status (26)

Country Link
US (5) US20050101770A1 (es)
EP (4) EP2123678A1 (es)
JP (4) JP4762148B2 (es)
KR (3) KR20120025618A (es)
CN (2) CN102010471A (es)
AR (3) AR046833A1 (es)
AT (1) ATE440867T1 (es)
AU (2) AU2004290044B2 (es)
CA (2) CA2812856A1 (es)
CY (1) CY1110557T1 (es)
DE (1) DE602004022855D1 (es)
DK (1) DK1694705T3 (es)
ES (1) ES2329907T3 (es)
HK (1) HK1087722A1 (es)
HR (1) HRP20090517T1 (es)
IL (3) IL175523A (es)
NO (1) NO20062672L (es)
NZ (1) NZ546632A (es)
PE (3) PE20090047A1 (es)
PL (1) PL1694705T3 (es)
PT (1) PT1694705E (es)
RS (1) RS51180B (es)
SG (1) SG155205A1 (es)
SI (1) SI1694705T1 (es)
WO (2) WO2005047324A2 (es)
ZA (1) ZA200603681B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2429769C (en) * 2000-12-07 2016-04-26 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
WO2002057283A1 (en) * 2001-01-19 2002-07-25 Baylor College Of Medecine Methods and compositions in breast cancer diagnosis and therapeutics
WO2003075952A1 (en) * 2002-03-05 2003-09-18 Board Of Regents, The University Of Texas System Methods of enhancing immune induction involving mda-7
WO2005082396A2 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
BRPI0418311B8 (pt) * 2004-02-23 2021-06-22 Synthes Ag parafuso de osso
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
JP2008531481A (ja) * 2005-02-08 2008-08-14 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム 癌の治療のための、ｍｄａ−７を含む組成物および方法
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
CA2620802A1 (en) 2005-08-31 2007-03-08 Schering Corporation Engineered anti-il-23 antibodies
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
PL2066695T3 (pl) * 2006-09-05 2013-08-30 Lilly Co Eli Przeciwciała przeciwko miostatynie
KR20090088950A (ko) 2006-12-14 2009-08-20 쉐링 코포레이션 가공된 항-ｔｓｌｐ 항체
MX2009006879A (es) 2006-12-22 2009-07-03 Schering Corp Anticuerpos contra el cd200r.
CN101611025A (zh) 2006-12-22 2009-12-23 先灵公司 5,6-环化的吲哚衍生物及其使用方法
JP5079818B2 (ja) 2006-12-22 2012-11-21 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖおよび関連するウイルス疾患の治療または予防のための４，５−環インドール誘導体
AU2007339386B8 (en) * 2006-12-22 2013-12-05 Merck Sharp & Dohme Corp. 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
CN101663320A (zh) 2007-02-23 2010-03-03 先灵公司 工程改造的抗IL-23p19抗体
BRPI0807710B1 (pt) 2007-02-23 2021-12-14 Merck Sharp & Dohme Corp Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica
CN101675076B (zh) 2007-02-28 2013-09-18 默沙东公司 工程化的抗il-23r抗体
AR068106A1 (es) * 2007-08-29 2009-11-04 Schering Corp Derivados de indol 2-carboxi sustituidos y una composicion farmaceutica
KR20100065167A (ko) * 2007-08-29 2010-06-15 쉐링 코포레이션 바이러스 감염 치료용 2,3-치환된 아자인돌 유도체
CA2697375A1 (en) * 2007-08-29 2009-03-12 Schering Corporation 2, 3-substituted indole derivatives for treating viral infections
US8765757B2 (en) * 2007-11-16 2014-07-01 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
WO2009064852A1 (en) * 2007-11-16 2009-05-22 Schering Corporation 3-aminosulfonyl substituted indole derivatives and methods of use thereof
AR072088A1 (es) * 2008-06-13 2010-08-04 Schering Corp Derivados de indol triciclicos y sus metodos de uso
US8337842B2 (en) * 2008-09-04 2012-12-25 Vet Therapeutics, Inc. Monoclonal antibodies
US8679492B2 (en) * 2009-02-23 2014-03-25 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to CD19 and their uses
EP2435424B1 (en) 2009-05-29 2015-01-21 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
BR112012004823B1 (pt) 2009-09-03 2021-11-30 Merck Sharp & Dohme Corp Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica
EP2503881B1 (en) 2009-11-25 2015-05-13 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
AU2010323037B2 (en) 2009-11-30 2015-01-29 Biotest Ag Humanized anti-IL-10 antibodies for the treatment of systemic lupus erythematosus (SLE)
CA2785488A1 (en) 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
WO2011103441A1 (en) 2010-02-18 2011-08-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2545060B1 (en) 2010-03-09 2015-11-25 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
CN103347894B (zh) 2010-06-19 2017-05-10 纪念斯隆-凯特林癌症中心 抗gd2抗体
EP2598149A4 (en) 2010-07-26 2014-09-10 Merck Sharp & Dohme SUBSTITUTED BIPHENYLENE COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
EP2621279B1 (en) 2010-09-29 2018-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
DK2643352T3 (en) * 2010-11-23 2018-07-30 Glaxo Group Ltd Antigen Binding Proteins for Oncostatin M (OSM)
CA3027071A1 (en) 2011-01-14 2013-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2012142085A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
CN102250243B (zh) * 2011-07-01 2013-08-28 华绍炳 抗白细胞介素-15抗体
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
US20140378416A1 (en) 2011-09-14 2014-12-25 Michael P. Dwyer Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
US9512405B2 (en) 2011-12-14 2016-12-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Non-enzymatic method for isolating human adipose-derived stromal stem cells
EP2968545B1 (en) 2013-03-15 2019-03-06 Memorial Sloan Kettering Cancer Center High affinity anti-gd2 antibodies
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
CN105277638A (zh) * 2014-07-22 2016-01-27 沈鹤霄 一种单克隆抗体IgG质谱测序方法
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016196178A1 (en) * 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. Combination of an anti-il-10 antibody and a cpg-c type oligonucleotide for treating cancer
RU2017145558A (ru) 2015-05-29 2019-07-01 Мерк Шарп И Доум Корп. Комбинация антагониста pd-1 и олигонуклеотида типа cpg-c для лечения рака
SG10201911035QA (en) 2015-11-18 2020-01-30 Merck Sharp & Dohme Pd1 and/or lag3 binders
MX2018007406A (es) 2015-12-16 2018-08-15 Merck Sharp & Dohme Anticuerpos anti-lag3 y fragmentos de enlace al antigeno.
EP3394099A4 (en) * 2015-12-22 2019-11-27 Merck Sharp & Dohme Corp. Formulations of Manipulated Anti- IL-10 Antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
KR20200003107A (ko) 2017-05-02 2020-01-08 머크 샤프 앤드 돔 코포레이션 항-lag3 항체의 제제, 및 항-lag3 항체 및 항-pd-1 항체의 공동-제제
EP3697425A1 (en) 2017-10-18 2020-08-26 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Methods and compounds for improved immune cell therapy
EP3768725A4 (en) * 2018-03-20 2021-06-02 Wuxi Biologics Ireland Limited Novel anti-tim-3 antibodies
CA3200884A1 (en) 2020-11-18 2022-05-27 Astrazeneca Ab Steroid sparing
CN118043349B (zh) * 2021-06-11 2024-11-15 丰华生物有限公司 一种人源化抗人GPVI单克隆抗体Fab片段及其应用
WO2024091417A1 (en) * 2022-10-24 2024-05-02 Merck Sharp & Dohme Llc Human hyaluronidase 1 mutants

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
US6018036A (en) 1990-06-29 2000-01-25 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (Interleukin-10)
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
KR100271197B1 (ko) * 1991-08-06 2000-11-01 둘락 노먼 씨. 인터루킨-10동족체또는길항제를포함하는내독소-또는초항원유도된독성치료용의약제학적조성물
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
DK0671933T3 (da) * 1992-08-20 1998-09-23 Schering Corp Hidtil ukendte anvendelser af IL-10
DE19529026C2 (de) * 1995-07-28 1997-06-19 Robert Sabat Monoklonale Antikörper gegen humanes Interleukin-10
US7034121B2 (en) * 2000-01-27 2006-04-25 Genetics Institue, Llc Antibodies against CTLA4
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
WO2004006955A1 (en) * 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US7148038B2 (en) * 2001-10-16 2006-12-12 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof
JP2005530490A (ja) * 2002-03-29 2005-10-13 シェーリング　コーポレイション インターロイキン−５に対するヒトモノクローナル抗体および方法およびこれを含む組成物

Also Published As

Publication number Publication date
CN1906213A (zh) 2007-01-31
AU2011200606B2 (en) 2012-05-10
IL202682A0 (en) 2010-06-30
CA2545255C (en) 2013-06-25
WO2005047326A2 (en) 2005-05-26
SG155205A1 (en) 2009-09-30
JP2011087590A (ja) 2011-05-06
EP2292661A2 (en) 2011-03-09
KR20120023858A (ko) 2012-03-13
IL175523A0 (en) 2006-09-05
AU2004290044A1 (en) 2005-05-26
PE20090047A1 (es) 2009-01-26
IL175523A (en) 2011-01-31
EP1694705B1 (en) 2009-08-26
CN102010471A (zh) 2011-04-13
EP2123678A1 (en) 2009-11-25
AR074779A2 (es) 2011-02-09
US20120282253A1 (en) 2012-11-08
KR101175055B1 (ko) 2012-08-22
NO20062672L (no) 2006-06-09
US8226947B2 (en) 2012-07-24
JP2011062211A (ja) 2011-03-31
AR074780A2 (es) 2011-02-09
CY1110557T1 (el) 2015-04-29
DE602004022855D1 (de) 2009-10-08
IL202681A (en) 2011-10-31
CA2545255A1 (en) 2006-05-05
IL202681A0 (en) 2010-06-30
EP1694705A2 (en) 2006-08-30
CA2812856A1 (en) 2005-05-26
EP2128175A1 (en) 2009-12-02
ZA200603681B (en) 2010-01-27
US20070178097A1 (en) 2007-08-02
SI1694705T1 (sl) 2010-01-29
PL1694705T3 (pl) 2010-02-26
AU2004290044B2 (en) 2010-11-18
ES2329907T3 (es) 2009-12-02
JP2014014361A (ja) 2014-01-30
JP2008500020A (ja) 2008-01-10
CN100595212C (zh) 2010-03-24
WO2005047324A2 (en) 2005-05-26
HRP20090517T1 (en) 2009-10-31
RS51180B (sr) 2010-10-31
US8624013B2 (en) 2014-01-07
AU2011200606A1 (en) 2011-03-03
ATE440867T1 (de) 2009-09-15
JP4762148B2 (ja) 2011-08-31
PE20050925A1 (es) 2005-11-29
US20140112919A1 (en) 2014-04-24
KR20120025618A (ko) 2012-03-15
DK1694705T3 (da) 2009-12-07
US20100203049A1 (en) 2010-08-12
KR20060120093A (ko) 2006-11-24
EP2292661A3 (en) 2011-06-22
PT1694705E (pt) 2009-11-30
US7662379B2 (en) 2010-02-16
US20050101770A1 (en) 2005-05-12
NZ546632A (en) 2009-07-31
HK1087722A1 (en) 2006-10-20
AR046833A1 (es) 2005-12-28
WO2005047326A3 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
PE20090046A1 (es) Anticuerpo recombinante humanizado anti-interleuquina 10
RS52889B (sr) Terapijsko humano anti-il-1r1 monoklonsko antitelo
RS51468B (en) COMPLETE HUMAN ANTIBODIES FOR HUMANS 4-1BB (CD137)
CY1107708T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης
DE60325906D1 (de) Antikörper gegen parath-hormon (pth) und ihre verwendungen
NO942912L (no) Konstruksjon, kloning og ekspresjon av humaniserte, monoklonale antistoffer mot humant interleukin-5
RS52332B (en) HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS
CO5160384A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que comprende el mismo
IN2009KN02655A (es)
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
MY162171A (en) Humanized antibodies that recognize beta amyloid peptide
RS51829B (sr) Ljudska antitela specifična za interleukin 15 (il-15)
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
TR200101831T2 (tr) CTLA-4 için insan monoklonal antikorları.
RS54111B1 (en) ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES
RS54088B1 (en) B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
RS54271B1 (en) Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
PE20050727A1 (es) Anticuerpos dirigidos a c-met
RS20050834A (en) Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
RS51197B (sr) Anti-dual integrinska antitela, sastavi, metode i njihove upotrebe
CL2010000789A1 (es) Anticuerpo monoclonal anti integrina alfabeta6, que inhibe la union de alfav-beta-6al peptido asociado a latencia (pal); composicion; uso para tratar fibrosis, psoriasis, cancer, daño agudo de pulmon o sindrome de alpont; uso para deteccion de alfa-vbetas; hibridoma con n° de acceso atcc pta-3646 (div.sol.no. 513-03)
PE20120306A1 (es) Anticuerpos anti-egfr y vectores que los codifican
CO5660296A2 (es) Anticuerpos humanizados que reconocen el peptido beta amiloide
PE20220708A1 (es) Anticuerpos anti-cd73

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载